Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
Wednesday, January 18, 2023SciSparc Ltd a specialty clinicalstage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system today announced it has been granted an approval by the Soroka University Medical Center Soroka Med...
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis
Wednesday, January 18, 2023ATyr Pharma Inc a biotherapeutics company engaged in the discovery and development of firstinclass medicines from its proprietary tRNA synthetase platform today announced that the European Commission EC granted orphan drug designation for the company...
Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study
Tuesday, January 17, 2023Algernon Pharmaceuticals Inc a Canadian clinical stage pharmaceutical development company is pleased to advise that its subsidiary Algernon NeuroScience AGN Neuro has dosed the first subject in its Phase clinical study of an intravenous formulation...
Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast
Tuesday, January 17, 2023The Stock Day Podcast welcomed Acasti Pharma Inc a latestage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases CEO of the Company Jan DAlvise joined Stock Day host Everett Jolly
CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland
Thursday, January 12, 2023CNS Pharmaceuticals Inc a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system today announced an investigatorinitiated Phase b trial evaluating the C...
ProBioGen Collaborates with Boehringer Ingelheim on DirectedLuck® Transposase Technology
Tuesday, January 10, 2023ProBioGen announced today a new nonexclusive collaboration with Boehringer Ingelheim on ProBioGens DirectedLuck transposase technology ProBioGen and Boehringer Ingelheim have a long legacy of fruitful collaboration going back to when the company
Clarivate Identifies Fifteen Potential Blockbuster Drugs in Annual Drugs to Watch Report
Tuesday, January 10, 2023Clarivate Plc a global leader in providing trusted information and insights to accelerate the pace of innovation today announced the release of its annual Drugs to Watch report In its th year the Drugs to Watch report provides indepth predictive anal...
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Monday, January 09, 2023Context Therapeutics Inc a clinicalstage biopharmaceutical company advancing medicines for solid tumors and Lonza a global development and manufacturing partner to the pharma biotech and nutrition industries today announced that the companies are col...
SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center
Monday, January 09, 2023SciSparc Ltd a specialty clinicalstage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system today announced it has signed an agreement with the Soroka University Medical Center in BeerSheva...
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
Friday, January 06, 2023Alvotech a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Teva Pharmaceuticals a US affiliate of Teva Pharmaceutical Industries Ltd today announced that the US Food and Drug A...
